LIEBERBURG IVAN,CALLAWAY JIM,GRUNDMAN MICHAEL,LIEBERBURG Ivan,CALLAWAY Jim,GRUNDMAN Michael
申请号:
SI200731495
公开号:
SI2182983T1
申请日:
2007.07.27
申请国别(地区):
SI
年份:
2014
代理人:
摘要:
The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Abeta. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.